Quantum BioPharma (NASDAQ: QNTM) Added to Our Potential Breakout Watchlist on Approx 12% Early Move

*Sponsored by Quantum BioPharma Ltd

Why Quantum BioPharma (QNTM) Should Be on Your Radar

 This Morning!

Several potential drivers back Quantum BioPharma (NASDAQ: QNTM), including:

Lucid-MS Therapy: Quantum BioPharma (NASDAQ: QNTM)’s lead candidate, Lucid-MS, targets multiple sclerosis in a market expected to grow from $21B in 2024 to $38B by 2032.

unbuzzd™ Expansion: The company’s unbuzzd™ alcohol detox product, backed by a distribution deal and Kevin Harrington’s endorsement, is poised for significant market growth.

Growth Potential: Despite a market cap under $12M, Quantum BioPharma (NASDAQ: QNTM) is gaining recognition with its advancing projects.

Tight Float: After a reverse split, Quantum BioPharma (NASDAQ: QNTM)now has less than 1.7Mn shares available, increasing potential price fluctuations.

Recent Attention: Quantum BioPharma (NASDAQ: QNTM) has moved approximately 100% in the past week, marking a 136% (approx) rise since October 1, 2024, and trending above key moving averages.

October 23, 2024

Dear Reader,

Are you watching Quantum BioPharma (NASDAQ: QNTM) yet?

Quantum BioPharma (NASDAQ: QNTM) moved approximately 12%early this morning from $5.87 to $6.58, surpassing several key moving averages including its 5-Day: 6.38, 20-Day: 4.84, and 50-Day: 4.44.

(QNTM) has been added to our potential breakout watchlist.

With their 100-Day Moving average at 7.49, we need to keep a close eye on this one.

Yesterday, Quantum BioPharma (NASDAQ: QNTM) reached $8.86.

This is #1 on our watchlist this morning.

This little-known company has just launched a massive $700Mn lawsuit against several well-known institutions, accusing them of manipulation through “spoofing.”

Monday’s announcement could set the stage for significant developments ahead.

And now, it’s time to reveal the company at the center of it:

Consider placing Quantum BioPharma (NASDAQ: QNTM) at the top of your watchlist early this morning.

Recently, Quantum BioPharma (NASDAQ: QNTM) underwent a reverse split, resulting in a razor-thin float with less than 1.7Mn shares available to the public.

Over the past week, Quantum BioPharma (NASDAQ: QNTM) has moved approximately 100%, trending above key moving averages (5-Day, 20-Day, 50-Day, and 100-Day) and reaching $8.86 yesterday—marking a 136%(approx) move since October 1, 2024.

With this surge in market recognition, the stage is set for potential volatility and significant movements as demand shifts.

Quantum BioPharma (NASDAQ: QNTM), with its market cap under $12M, might have flown under the radar—until now.

With a diverse portfolio of candidates at various stages of development, the company is committed to addressing some of the most complex medical challenges.

Through its subsidiary, Lucid Ps-ych-eceu-ticals Inc., Quantum BioPharma (NASDAQ: QNTM) is making significant progress with its lead compound, Lucid-MS, which plays a key role in the company’s mission to combat serious disorders affecting many people worldwide.

One of their most promising initiatives, Lucid-MS, is a patented chemical entity designed to target multiple sclerosis (MS), a chronic, often disabling disease that affects approximately 2.8Mn people globally.

The multiple sclerosis therapeutic market is projected to grow from $21B in 2024 to $38B by 2032, underscoring the increasing need for effective treatments for this debilitating condition.

Lucid-MS is designed to address the underlying cause of MS by preventing and reversing myelin degradation.

Myelin is a protective sheath that covers nerve fibers, and its degradation is a key mechanism in the development of multiple sclerosis.

Preclinical models have shown that Lucid-MS is a neuroprotective compound with the potential to halt or reverse myelin damage, offering hope for improved outcomes for those affected by MS and other neurodegenerative conditions.

Revolutionizing Alcohol Detoxification

Quantum BioPharma (NASDAQ: QNTM) is making notable advancements in the alcohol detox space with the development of unbuzzd™, a product designed to boost mental alertness and aid detoxification after alcohol consumption.

This innovative solution addresses a pressing public health issue, blending scientific research with practical applications in alcohol metabolism.

In 2023, unbuzzd™ was introduced to the market by Celly Nutrition Corp., a spin-off of Quantum BioPharma (NASDAQ: QNTM), with the company retaining a 25.71% stake.

The product, created by industry leaders from Coca-Cola and Celsius Holdings, has already secured a major distribution agreement with FUSION Distribution Group, bringing unbuzzd™ to Puerto Rico, the Caribbean, and parts of Central and South America.

Currently available as Ready-to-Mix powder sticks on Amazon, unbuzzd™ will soon be available in Ready-to-Drink cans.

With distribution set to expand through major retailers like Walmart and Costco, unbuzzd™ is positioned to transform the alcohol detox market by providing a much-needed solution for consumers seeking to metabolize alcohol faster and enhance mental clarity.

Harrington, renowned for identifying groundbreaking products, believes unbuzzd™ could change how society approaches alcohol consumption and detoxification.

Harrington remarked on the product’s potential, noting that unbuzzd™ could offer a vital solution for those who consume alcohol, with the ability to reduce its harmful effects and improve lives on a large scale.

In his testimonial, Harrington recalled a real-life example, saying, “I saw someone intoxicated take this product. Within minutes, their demeanor shifted, and their blood alcohol levels dropped. unbuzzd™ has the power to revolutionize the alcohol detox space.”

With a strong focus on advancing solutions for multiple sclerosis, neurodegenerative diseases, and alcohol misuse, Quantum BioPharma (NASDAQ: QNTM) continues to solidify its role in biopharmaceutical innovation. As the company expands its portfolio of transformative treatments, its ongoing progress in these areas warrants close attention.

5 reasons to consider adding Quantum BioPharma (NASDAQ: QNTM) to your watchlist for today…

1. Limited Share Availability: Quantum BioPharma (NASDAQ: QNTM) recently completed a reverse split, leaving less than 1.7Mn shares available to the public, creating the potential for notable price shifts as demand fluctuates.

2. Recent Attention: Over the past week, Quantum BioPharma (NASDAQ: QNTM) has seen an approximate 100% move, trending above key moving averages and showing a 136% (approx) move since October 1, 2024, highlighting strong momentum.

3. Higher Potential for Growth: Despite a market cap under $12M, Quantum BioPharma (NASDAQ: QNTM) has remained relatively unnoticed, but its current projects are positioning it for greater recognition.

4. Game-Changing Multiple Sclerosis Therapy: The company’s lead candidate, Lucid-MS, is designed to combat multiple sclerosis, a condition within a market expected to grow significantly from $21B in 2024 to $38B by 2032.

5. Revolutionary Solution: Quantum BioPharma (NASDAQ: QNTM)’s unbuzzd™ product, developed by its subsidiary Celly Nutrition, helps support alcohol detoxification. Backed by a distribution deal and endorsement from Kevin Harrington, unbuzzd™ is positioned for significant market expansion.

Pay attention to Quantum BioPharma (NASDAQ: QNTM) as it steadily advances with its pioneering developments in biopharmaceuticals.

With a tight public float of under 1.7Mn shares, Quantum BioPharma (NASDAQ: QNTM) presents the potential for significant movements as if demand begins to shift. The company’s recent market attention has been impressive, with an approx 100% move over the past week marking a 136% (approx) move since October 1, 2024. Despite flying under the radar with a market cap below $12M, Quantum BioPharma (NASDAQ: QNTM)’s ongoing projects are bringing the company into the spotlight.

Leading these developments is Lucid-MS, a promising treatment for multiple sclerosis, poised to make an impact in a market expected to grow to $38B by 2032.

Additionally, unbuzzd™, the company’s al-co-hol detox product developed by its subsidiary, is gaining momentum with a major distribution deal and the endorsement of Kevin Harrington, enhancing its growth potential in the wellness space.

Quantum BioPharma (NASDAQ: QNTM) has been added to our potential breakout watchlist.

Alex Ramsay

Co-Founder / Managing Editor

Krypton Street Newsletter

KryptonStreet.com (“KryptonStreet” or “KS” ) is owned by Media 1717 LLC, a single member limited liability company. Data is provided from third-party sources and KryptonStreet is not responsible for its accuracy. Make sure to always do your own research and due diligence on any day and swing profile KS brings to your attention. Any emojis used do not have a specific defined meaning, and may be used inconsistently. We do not provide personalized in.vest.ment advice, are not in.vest.ment advisors, and any profiles we mention are not suitable for all in.vest.ors.

The owner of Media 1717 LLC owns and operates kryptonstreet . com (“KS”). From time to time, KS will publicly disseminate information about a company via website, email, SMS and other points of media.

Please see important disclosure information here: kryptonstreet.com/disclaimer/

*Pursuant to an agreement between Media 1717 LLC and TD Media LLC, Media 1717 LLC has been hired by TD Media LLC for a period beginning on 10/22/2024 and ending on 10/23/2024 to publicly disseminate information about (QNTM:US) via digital communications. Under this agreement, Media 1717 LLC has been paid seven thousand five hundred USD (“Funds”) to disseminate information about (QNTM:US) via digital communications. These Funds were part of the funds that TD Media LLC received from Quantum BioPharma Ltd., the issuer. To date Media 1717 LLC has been paid twenty-seven thousand five hundred USD (“Funds”). Neither Media 1717 LLC, TD Media LLC and their member own shares of (QNTM:US). Please see important disclosure information here: https://kryptonstreet.com/qntm-disclosure-v2/